{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:14:01Z","timestamp":1784783641738,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.06.075","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T01:45:49Z","timestamp":1656899149000},"page":"4889-4896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study"],"prefix":"10.1016","volume":"40","author":[{"given":"Maria","family":"Xiridou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Meiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Matser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Op de Coul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.vaccine.2022.06.075_b0005","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1016\/j.vaccine.2017.04.068","article-title":"Targeted outreach hepatitis B vaccination program in high-risk adults: the fundamental challenge of the last mile","volume":"35","author":"Mangen","year":"2017","journal-title":"Vaccine"},{"key":"#cr-split#-10.1016\/j.vaccine.2022.06.075_b0010.1","unstructured":"Staritsky LE, Visser M, van Aar F, Op de Coul E, Heijne J, van Wees D, et al. Sexually transmitted infections in the Netherlands in 2020. Report number 2021-0052. National Institute of Public Health and the Environment, Bilthoven, The Netherlands"},{"key":"#cr-split#-10.1016\/j.vaccine.2022.06.075_b0010.2","unstructured":"2021. <https:\/\/rivm.openrepository.com\/bitstream\/handle\/10029\/625007\/2021-0052.pdf> [accessed: 14 January 2022]."},{"key":"10.1016\/j.vaccine.2022.06.075_b0015","unstructured":"National Institute of Public Health and the Environment (RIVM). The National Immunisation Programme in the Netherlands. Surveillance and developments in 2020\u20132021. Report 2021-0055. Edited by Pluijmaekers AJM, de Melker HE. Bilthoven; 2021. <https:\/\/www.rivm.nl\/en\/national-immunisation-programme\/surveillance-and-developments> [accessed: 14 January 2022]."},{"key":"10.1016\/j.vaccine.2022.06.075_b0020","doi-asserted-by":"crossref","unstructured":". Meiberg AE, Urbanus AT. How to reach high behavioral risk groups for HBV-vaccination: combining offline and online strategies. In: Conference of the European public health association. Marseille; 2019. Poster presentation.","DOI":"10.1093\/eurpub\/ckz186.512"},{"key":"10.1016\/j.vaccine.2022.06.075_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.04.015","article-title":"Decrease in viral hepatitis diagnoses during the COVID-19 pandemic in the Netherlands","author":"Sonneveld","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2022.06.075_b0030","unstructured":"National Institute of Public Health and the Environment (RIVM). Thermometer sexual health November 2021. <https:\/\/www.rivm.nl\/documenten\/thermometer-seksuele-gezondheid-november-2021> [accessed: 14 January 2022]."},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2022.06.075_b0035","first-page":"A26","article-title":"Changes in MSM\u2019s sexual activity, PrEP use, and access to HIV\/STI testing during and after the first Dutch COVID-19 lockdown","volume":"97","author":"Adam","year":"2021","journal-title":"Sex Transmit Infect"},{"key":"10.1016\/j.vaccine.2022.06.075_b0040","unstructured":"Adam PCG, Zuilhof W, Den Daas C, Op de Coul E, Zantkuijl P, Paolucci J, et al. Reduction in the magnitude of COVID-19-associated changes in sexual activity and disruption in HIV\/STI testing or PrEP use among MSM responding to the 2nd COVID-19, sex and intimacy survey. in: National conference on HIV. Virtual; 2021. Oral presentation."},{"key":"10.1016\/j.vaccine.2022.06.075_b0045","unstructured":"de la Court F, Boyd A, Coyer L, van den Elshout MA, de Vries H, Matser A, et al. Three periods of COVID-19 restrictions in 2020 and their impact on sexual healthcare use, PrEP use, and STI incidence among MSM. In: National conference on HIV. Virtual; 2021. Oral presentation."},{"issue":"21","key":"10.1016\/j.vaccine.2022.06.075_b0050","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1016\/j.vaccine.2021.04.008","article-title":"Ending risk-group HBV vaccination for MSM after the introduction of universal infant HBV vaccination: a mathematical modelling study","volume":"39","author":"Xiridou","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.075_b0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/QAD.0b013e32834f9d7c","article-title":"Less decrease in risk behaviour from pre-HIV to post-HIV seroconversion among MSM in the combination antiretroviral therapy era compared with the pre-combination antiretroviral therapy era","volume":"26","author":"Heijman","year":"2012","journal-title":"AIDS"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2022.06.075_b0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.vaccine.2003.09.001","article-title":"Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers","volume":"22","author":"Floreani","year":"2004","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.075_b0065","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/sextrans-2016-052918","article-title":"Frequency and determinants of consistent STI\/HIV testing among men who have sex with men testing at STI outpatient clinics in the Netherlands: a longitudinal study","volume":"93","author":"Visser","year":"2017","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2022.06.075_b0070","unstructured":"Government of the Netherlands. Coronavirus COVID-19. <https:\/\/www.government.nl\/topics\/coronavirus-covid-19> [accessed: 14 January 2022]."},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.075_b0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/OLQ.0000000000001551","article-title":"How the disruption in STI care due to the COVID-19 pandemic could lead to increased STI transmission among MSM in the Netherlands: a mathematical modelling study","volume":"49","author":"Xiridou","year":"2022","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2022.06.075_b0080","unstructured":"Kloek M, Waterman L, Anonymous Sexworker, Spek E, Hendriks S, Luhrs Y, et al. Research on the impact of corona on sexwork in the Netherlands. Report published online 1 December 2021. In Dutch. <https:\/\/www.soaaids.nl\/files\/2021-12\/Rapport_Onderzoek_impact_Corona_Sekswerkers.pdf> [accessed: 15 June 2022]."},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.075_b0085","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/infdis\/jiab051","article-title":"Projected HIV and bacterial sexually transmitted infection incidence following COVID-19-related sexual distancing and clinical service interruption","volume":"223","author":"Jenness","year":"2021","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.075_b0090","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S2352-3018(20)30211-3","article-title":"Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models","volume":"7","author":"Jewell","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2022.06.075_b0095","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S2352-3018(21)00022-9","article-title":"The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study","volume":"8","author":"Mitchell","year":"2021","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.075_b0100","doi-asserted-by":"crossref","first-page":"e25697","DOI":"10.1002\/jia2.25697","article-title":"The impact of disruptions due to COVID-19 on HIV transmission and control among men who have sex with men in China","volume":"24","author":"Booton","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.075_b0105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.075_b0110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gut.2007.128496","article-title":"Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years","volume":"57","author":"Fattovich","year":"2008","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.075_b0115","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.vaccine.2022.06.075_b0120","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients","volume":"97","author":"Fattovich","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"15","key":"10.1016\/j.vaccine.2022.06.075_b0125","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.075_b0130","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.075_b0135","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<901::AID-CNCR15>3.0.CO;2-Z","article-title":"Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis","volume":"83","author":"Benvegn\u00f9","year":"1998","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.075_b0140","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00004836-200205000-00018","article-title":"Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation","volume":"34","author":"Hui","year":"2002","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.075_b0145","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/j.1572-0241.2006.00769.x","article-title":"Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis","volume":"101","author":"Kanwal","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.075_b0150","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1440-1746.2005.03813.x","article-title":"Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression","volume":"20","author":"Lin","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"issue":"1337","key":"10.1016\/j.vaccine.2022.06.075_b0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1098\/rspb.1993.0102","article-title":"The influence of age on the development of the hepatitis B carrier state","volume":"253","author":"Edmunds","year":"1993","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.vaccine.2022.06.075_b0160","series-title":"Viral hepatitis","first-page":"169","article-title":"Serodiagnostic profiles of viral hepatitis","author":"Overby","year":"1982"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.06.075_b0165","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(03)00139-9","article-title":"Natural history of hepatitis B","volume":"39","author":"Fattovich","year":"2003","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.075_b0170","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.075_b0175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state","volume":"151","author":"McMahon","year":"1985","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.06.075_b0180","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/0264-410X(95)93549-O","article-title":"Hepatitis B prevention in Europe: a preliminary economic evaluation","volume":"13","author":"Van Damme","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.075_b0185","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"9865","key":"10.1016\/j.vaccine.2022.06.075_b0190","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.075_b0195","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2022.06.075_b0200","unstructured":"World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. In. Geneva; 2015. <https:\/\/www.who.int\/hiv\/pub\/hepatitis\/hepatitis-b-guidelines\/en\/>. [accessed: 14 January 2022]."},{"key":"10.1016\/j.vaccine.2022.06.075_b0205","first-page":"D2047","article-title":"Diagnosis, follow-up, and reference of patients with hepatitis B and C","volume":"162","author":"Hofman","year":"2018","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.vaccine.2022.06.075_b0210","unstructured":"Dutch Association of Gastrointestinal Liver Physicians. Guidelines treatment of chronic hepatitis B virus infection; 2012. <https:\/\/www.mdl.nl\/sites\/www.mdl.nl\/files\/richtlijnen\/Richtlijn_HBV_nieuwe_inzichten_2012.pdf> [accessed: 14 January 2022]."},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.075_b0215","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.075_b0220","doi-asserted-by":"crossref","first-page":"e0133232","DOI":"10.1371\/journal.pone.0133232","article-title":"Changing patterns of undiagnosed HIV infection in the Netherlands: who benefits most from intensified HIV test and treat policies?","volume":"10","author":"Op de Coul","year":"2015","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.075_b0225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S0950268800001497","article-title":"Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas","volume":"117","author":"Edmunds","year":"1996","journal-title":"Epidemiol Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.075_b0230","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","article-title":"Requirements for global elimination of hepatitis B: a modelling study","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.075_b0235","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/cit145","article-title":"Prophylactic effect of antiretroviral therapy on hepatitis B virus infection","volume":"56","author":"Gatanaga","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.075_b0240","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/QAD.0000000000000180","article-title":"Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection","volume":"28","author":"Heuft","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2022.06.075_b0245","unstructured":"Mizushima D, Takano M, Uemura H, Yanagawa Y, Aoki T, Watanabe K, et al. Prophylactic effect of PrEP against HBV infection among MSM. In: Conference on retroviruses and opportunistic infections. Virtual; 2020."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:34Z","timestamp":1759403794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22008477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":50,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22008477"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}